Trials / Completed
CompletedNCT01233622
Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
A Multi-center, Randomized, Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin 50 mg Bid as add-on Therapy to Metformin Plus Glimepiride in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 317 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with Type 2 Diabetes (T2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-11-03
- Last updated
- 2017-02-23
Locations
55 sites across 9 countries: Australia, Germany, Hungary, Italy, Mexico, Philippines, Romania, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01233622. Inclusion in this directory is not an endorsement.